Pacira BioSciences (NASDAQ:PCRX) Given New $32.00 Price Target at Needham & Company LLC

Pacira BioSciences (NASDAQ:PCRX) had its price objective lifted by investment analysts at Needham & Company LLC from $30.00 to $32.00 in a report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s price objective suggests a potential upside of 33.06% from the company’s previous close.

Other equities research analysts also recently issued reports about the company. Barclays reduced their price target on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research note on Tuesday, January 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a report on Wednesday, December 4th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Stock Performance

Pacira BioSciences stock opened at $24.05 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. The firm has a market capitalization of $1.11 billion, a P/E ratio of -11.85 and a beta of 0.80. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The company’s 50-day moving average is $23.16 and its 200 day moving average is $18.63.

Institutional Investors Weigh In On Pacira BioSciences

Several large investors have recently modified their holdings of the business. State of Wyoming boosted its stake in shares of Pacira BioSciences by 8.0% during the fourth quarter. State of Wyoming now owns 6,566 shares of the company’s stock valued at $124,000 after purchasing an additional 487 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Pacira BioSciences by 3.1% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,077 shares of the company’s stock valued at $491,000 after acquiring an additional 794 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after acquiring an additional 918 shares during the period. Finally, Sterling Capital Management LLC raised its position in shares of Pacira BioSciences by 779.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,363 shares of the company’s stock worth $26,000 after acquiring an additional 1,208 shares in the last quarter. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.